135 related articles for article (PubMed ID: 3144537)
1. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
2. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
3. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
7. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
[TBL] [Abstract][Full Text] [Related]
8. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
10. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
11. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.
Heizmann P; Dell D; Eggers H; Gora R
J Chromatogr; 1990 Apr; 527(1):91-101. PubMed ID: 2114419
[TBL] [Abstract][Full Text] [Related]
12. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
Wise R; Kirkpatrick B; Ashby J; Griggs DJ
Antimicrob Agents Chemother; 1987 Feb; 31(2):161-3. PubMed ID: 3105446
[TBL] [Abstract][Full Text] [Related]
15. Fleroxacin concentrations in myometrium, ovary and fallopian tube.
Portmann R; Hansz C; Stiglmayer R; Weidekamm E
J Antimicrob Chemother; 1989 Apr; 23(4):662-4. PubMed ID: 2501273
[No Abstract] [Full Text] [Related]
16. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.
Naber KG; Theuretzbacher U; Kinzig M; Savov O; Sörgel F
Antimicrob Agents Chemother; 1998 Jul; 42(7):1659-65. PubMed ID: 9661000
[TBL] [Abstract][Full Text] [Related]
20. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
Baba S; Mori Y; Maruo T
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():195-7. PubMed ID: 3144538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]